Ascendis Pharma Announces $400 Million Share Repurchase Program Authorization

On September 14, 2026, Ascendis Pharma A/S announced that its Board of Directors has authorized a share repurchase program of up to $400 million of the Company’s ordinary shares. Under the authorized program, the company may purchase shares through various methods, including open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, or 10b5-1 trading plans. The timing and exact volume of the repurchases will be determined by management based on market conditions, share price, and other relevant factors. The program does not obligate Ascendis to acquire any specific number of shares and may be modified, suspended, or terminated at any time without prior notice. This capital allocation strategy reflects the company's current financial positioning and management's discretion in returning value to shareholders. The company also highlighted various forward-looking risks, including dependence on third-party manufacturers and regulatory review uncertainties, which could impact its future operations and the execution of the repurchase plan.